33 results on '"Baird, John H."'
Search Results
2. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma
3. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
4. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
5. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
6. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
7. Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma.
8. Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
9. 5 - Microbiology
10. Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma.
11. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis
12. Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
13. Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
14. Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
15. Contributors
16. Voriconazole-induced periostitis after allogeneic stem cell transplantation
17. Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide
18. An Unusual Cause of Epistaxis: Paranasal Sinus Myeloid Sarcoma
19. Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease.
20. 5 - Microbiology
21. PB2346: ZUMA‐24: A PHASE 2, OPEN‐LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING.
22. Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity
23. CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
24. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
25. The Hemorrhage that Wasn't: Polycythemia Presenting as a Pseudointracranial Hemorrhage in Pedestrian vs Automobile Trauma Alert.
26. End-Alveolar Carbon Monoxide As a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease
27. Contributors
28. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
29. Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.
30. COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies.
31. Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.
32. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.
33. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.